New Research on Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020-2026 Industry Size, Share, Types, Regional Analysis, Manufacturers…

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market was estimated to be valued at USD XX million in 2018 and is projected to reach USD XX million by 2026, at a CAGR of XX% during 2020 to 2026. Increasing prevalence of chronic diseases and adaptation of advanced technology are driving the market growth. However high cost of the therapy might restraint the market growth

For Sample Copy of this Report @ https://www.orianresearch.com/request-sample/1131253

What You Can Expect From Our Report:

Autologous Stem Cell and Non-Stem Cell Based Therapies Industry report offers a comprehensive insight into the development policies and plans in addition to manufacturing processes and cost structures. On the basis of product, this report displays the cost structure, sales revenue, sales volume, gross margin, market share and growth rate.

Report Covers Market Segment by Manufacturers:

Report Covers Market Segment by Types:

Global Autologous Stem Cell and Non-Stem Cell Based Therapies Industry 2020 Market Research Report is spread across 121 pages and provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Order Copy of this Report 2020 @ https://www.orianresearch.com/checkout/1131253

Report Covers Market Segment by Applications:

Key Benefits of the Report:

Target Audience:

Inquire more about Autologous Stem Cell and Non-Stem Cell Based Therapies Market report @ https://www.orianresearch.com/enquiry-before-buying/1131253

Research Methodology

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective like analyst report of investment banks. The secondary research forms the base of our study where we conducted extensive data mining, referring to verified data sources such as white papers government and regulatory published materials, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factor, investment, market dynamics including technical scenario, consumer behavior, and end use industry trends and dynamics, capacity Types, spending were taken into consideration.

We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the

Key Industry Participants (KIPs) which typically include:

Table of Content

1 Executive Summary

2 Methodology And Market Scope

3 Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Outlook

4 Autologous Stem Cell and Non-Stem Cell Based Therapies Market By End User

5 Autologous Stem Cell and Non-Stem Cell Based Therapies Market Type

6 Autologous Stem Cell and Non-Stem Cell Based Therapies Market Regional Outlook

7 Competitive Landscape

End of the report

Disclaimer

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us:

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (415) 830-3727 | UK: +44 020 8144-71-27

Email: [emailprotected]

Read more here:
New Research on Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2020-2026 Industry Size, Share, Types, Regional Analysis, Manufacturers...

Mesenchymal Stem Cells Market Market Will Witness Substantial Growth in the Upcoming Years – 3rd Watch News

CMI announced that its published an exclusive report namely Global Mesenchymal Stem Cells Market by Manufacturers, Regions, Type, and Application, Forecast to 2027 in its research database with report summary, table of content, research methodologies, and data sources. The research study offers a substantial knowledge platform for entrants and investors as well as veteran companies, manufacturers functioning in the Worldwide Mesenchymal Stem Cells Market. This is an informative study covering the market with an in-depth analysis and portraying the current state of affairs in the industry.

Download PDF Brochure Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/720

The report presents an overview of Mesenchymal Stem Cells Market consist of objectives study and definition of Mesenchymal Stem Cells. The next section focuses on market size, region-wise Mesenchymal Stem Cells growth rate estimation from 2020-2027.

This research report categorizes the global market by players/brands, regions, types, and applications. This report also studies the global market status, competition landscape, Market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors, and Porters Five Forces Analysis.

Key Manufacturers Analysis:Pluristem Therapeutics, LonzaThermo, Fisher, ATCC, Bio-Techne, MilliporeSigma, Genlantis, Celprogen, Cell Applications, PromoCell GmbH, Cyagen Biosciences, Human Longevity Inc., Axol Bioscience, Cytori Therapeutics, Eutilex Co.Ltd., ID Pharma Co. Ltd., BrainStrom Cell Therapeutics, Cytori Therapeutics Inc., Neovii Biotech, Angel Biotechnology, California Stem Cell Inc., Stemcelltechnologies Inc., and Celgene Corporation Inc.

The top manufacturers, exporters, and retailers (if applicable) around the world are analyzed for this research report with respect to their company profile, product portfolio, capacity, price, cost, and revenue.

Mesenchymal Stem Cells Market 2020 Forecast to 2027 Market Segment by Regions, regional analysis covers

North America (the USA, Canada, and Mexico) Europe (Germany, France, UK, Russia, and Italy) Asia-Pacific (China, Japan, Korea, India, and Southeast Asia) South America (Brazil, Argentina, Columbia, etc.) The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Following market aspects are enfolded in Global Mesenchymal Stem Cells Market Report:

A wide summarization of the Global Mesenchymal Stem Cells Market. The present and forecasted regional market size data based on applications, types, and regions. Market trends, drivers, and challenges for the Global Mesenchymal Stem Cells Market. Analysis of company profiles of Top major players functioning in the market.

Mesenchymal Stem Cells Market report passes on a fundamental overview of the Market including its definition, applications, and advancement. Furthermore, the Industry report investigates the ecumenical Major Mesenchymal Stem Cells Market players in detail. Mesenchymal Stem Cells Market report gives key bits of the Cautiousness and subsisting status of the Players and is a basic Source obviously and heading for Companies and people energized by the Industry.

Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/720

Key questions answered in Report:-

Mesenchymal Stem Cells Business Analysis Including Size, Share, Key Drivers, Growth Opportunities and Trends 2020- 2027 Consumption Analysis of Mesenchymal Stem Cells, Guidelines Overview and Upcoming Trends Forecast till 2027 Mesenchymal Stem Cells Market Top Companies Sales, Price, Revenue and Market Share Outlook Mesenchymal Stem Cells Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast 2027 Analytical Overview, Growth Factors, Demand and Trends Mesenchymal Stem Cells by Technology, Opportunity Analysis and Industry Forecasts, 2020- 2027 Analysis Covering Market Size, Growth Factors, Demand, Trends and Forecast Mesenchymal Stem Cells Overview, Raw Materials Analysis, Market Drivers and Opportunities In-depth Research on Market Size, Trends, Emerging Growth Factors and Forecasts.

Conclusively, this report will provide you a clear view of each fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

Contact:

Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Email: [emailprotected] United States of America: +1-206-701-6702 United Kingdom: +44-020-8133-4027 Japan: +050-5539-1737 India: +91-848-285-0837

Stay Home. Stay Safe. Save Lives.

View post:
Mesenchymal Stem Cells Market Market Will Witness Substantial Growth in the Upcoming Years - 3rd Watch News

Global Stem Cell Therapy Market Report Examines Analysis By Size, Share, Latest Trends, Future Growth, Top Key Players And Forecast To 2027 – Jewish…

The New Report Titled as Stem Cell Therapy Market published by Global Marketers, covers the market landscape and its evolution predictions during the forecast period. The report objectives to provide an overview of global Stem Cell Therapy Market with detailed market segmentation by solution, security type, application and geography. The Stem Cell Therapy Market is anticipated to eyewitness high growth during the forecast period. The report delivers key statistics on the market status of the leading market players and deals key trends and opportunities in the market.

Request For Free Sample Report: @ https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#request_sample

This research report also includes profiles of major companies operating in the global market. Some of the prominent players operating in the Global Stem Cell Therapy Market are:

Celgene Corporation Osiris Therapeutics, Inc. Pharmicell Co., Ltd MEDIPOST Co., Ltd. Promethera Biosciences Fibrocell Science, Inc. Holostem Terapie Avanzate S.r.l. Cytori Therapeutics Nuvasive, Inc. RTI Surgical, Inc. Anterogen Co., Ltd. RTI Surgical, Inc

The Stem Cell Therapy Market for the regions covers North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Regional breakdown has been done based on the current and forthcoming trends in the global Stem Cell Therapy Market along with the discrete application segment across all the projecting region.

Ask For Discount: https://www.reportspedia.com/discount_inquiry/discount/57925

The Type Coverage in the Market are:

Adult Stem Cells Human Embryonic Induced Pluripotent Stem Cells Very Small Embryonic Like Stem Cells

Market Segment by Applications, covers:

Regenerative Medicine Drug Discovery and Development

Some Major TOC Points:

Chapter 1. Stem Cell Therapy Market Report Overview

Chapter 2. Global Stem Cell Therapy Market Growth Trends

Chapter 3. Market Share by Key Players

Chapter 4. Stem Cell Therapy Market Breakdown Data by Type and Application

Chapter 5. Market by End Users/Application

Chapter 6. COVID-19 Outbreak: Stem Cell Therapy Industry Impact

Chapter 7. Opportunity Analysis in Covid-19 Crisis

Chapter 9. Market Driving Force

Continue for TOC

Do you want any other requirement or customize the report, Do Inquiry Here: https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#inquiry_before_buying

Key questions Answered in this Stem Cell Therapy Market Report:

What will be the Stem Cell Therapy Market growth rate and value in 2020?

What are the key market predictions?

What is the major factors of driving this sector?

What are the situations to market growth?

Major factors covered in the report:

Global Stem Cell Therapy Market summary

Economic Impact on the Industry

Stem Cell Therapy Market Competition in terms of Manufacturers

Stem Cell Therapy Market Analysis by Application

Marketing Strategy comprehension, Distributors and Traders

Study on Market Research Factors

Table of Content & Report Detail @ https://www.reportspedia.com/report/business-services/2015-2027-global-stem-cell-therapy-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/57925#table_of_contents

See the rest here:
Global Stem Cell Therapy Market Report Examines Analysis By Size, Share, Latest Trends, Future Growth, Top Key Players And Forecast To 2027 - Jewish...

In Remission for 10 Years: Long-term Data on CAR-T Therapy – Medscape

When a patient with cancer hears there isn't much left that doctors can do, it always stays fresh in the mind.

Doug Olson was first diagnosed with chronic lymphocytic leukemia (CLL) over 20 years ago, in 1996. For several years, his doctors used the watch-and-wait approach. But then his cancer progressed and needed treatment. By 2010, it had mutated so much that it no longer responded to standard therapy.

He was rapidly running out of options. Back then, the only treatment left was a bone marrow transplant. Without one, his doctors said, he would have 1 or 2 years left to live.

"I was really trying to avoid a bone marrow transplant. You're playing your last card if that doesn't work. It's a pretty rough procedure," Olson told Medscape Medical News.

Looking back, Olson counts himself as lucky for being in the right place, at the right time, with the right doctor. His oncologist was David Porter, MD, the principal investigator on a trial at the University of Pennsylvania that was investigating a brand new approach to treating cancer: chimeric antigen receptor (CAR) T-cell therapy.

CAR T-cell therapy uses a patient's own T cells engineered to express a receptor that targets proteins on cancer cells. CAR T cells are considered "living drugs" because they expand inside the body and stick around for years maybe for a lifetime to fight the cancer if it tries to come back.

"I was certainly intrigued by the approach. It had worked in mice, and it was the sort of thing that looked like it would work," Olson recalled.

Science is not a foreign language to Olson. He holds a PhD in medicinal chemistry, spent most of his career in the in vitro diagnostics industry, and currently acts as chief executive officer of Buhlmann Diagnostics Corp.

So he read the clinical protocol for the first in-human trial of CAR T cells and agreed to become patient number two.

Olson's T cells were harvested, engineered to attack the CD19 antigen found on malignant and normal B lymphocytes, and then were expanded into millions in the lab. After undergoing preconditioning with chemotherapy to minimize rejection and boost the CAR T cells' expansion inside the body, he received several infusions of the new therapy over the course of 3 days.

Nothing really happened for 2 weeks. Then he developed severe flu-like symptoms so bad that he was hospitalized.

Ironically, getting sick was a sign that the CAR T cells were working. Olson was experiencing one of the main short-term effects of CAR T-cell therapy: cytokine release syndrome. Symptoms include extremely high fevers and dangerous drops in blood pressure that can potentially cause end-organ damage.

In the early trials of these products, some patients experienced such a severe reaction that they needed intensive care, and some died. With increasing clinical experience, doctors have learned to control the reaction with the use of steroids and interleukein-6 inhibitors such as tocilizumab (Actemra).

Fortunately for Olson, the reaction passed, and he was eventually discharged.

Then the "aha moment" happened. Four weeks after receiving the CAR T cells, Olson found out that he was cancer free.

"It still gives me shivers," he said. "Dr Porter said, 'Your bone marrow's completely free. We just can't find a cancer cell anywhere.' "

The remission has lasted, and it is now 10 years later.

Long-term data have been accumulating for these novel therapies since Olson's treatment in 2010. This is particularly important for CAR T-cell therapy, because of its longevity. Because these are living cells and are expected to persist in the body for years, there is great interest in longer-term data, especially the risks for toxicity.

The FDA requires clinical follow-up for at least 15 years for patients treated with CAR T-cell therapy or any other genetically modified cells.

So far, most of the experience with CAR T cells comes from anti-CD19-directed therapy, which has shown "remarkable" remission rates in the 50% to 85% range, said Nirali Shah, MD, head of the hematologic malignancies section of the Pediatric Oncology Branch at the National Cancer Institute (NCI).

The most recent results presented at this year's annual meeting of the American Society of Clinical Oncology support earlier efficacy data, she noted. In the longest follow-up to date, researchers reported remissions lasting over 9 years in patients with relapsed/refractory B-cell lymphoma or CLL treated with Kite's axicaptagene cilleucel (Yescarta), one of two anti-CD19-directed CAR T-cell therapies approved by the FDA in 2017 (the other is Novartis' tisagenlecleucel [Kymriah]).

This study included 43 patients and showed an overall remission rate of 76%. Complete remission was achieved in 54% of patients, and 22% had partial remission.

The other focus is long-term safety. Although some of the long-term adverse effects are known and are manageable, others fall into the theoretical realm. In early May 2020, the NCI held a multidisciplinary virtual conference on CAR T-cell therapy "to encourage collaborative research about the subacute and potentially long-term toxicity profile of these treatments."

"We know just a little at this point about late- and long-term effects of CAR-T therapy, because we are relatively early in the era of CAR T cells," said Merav Bar, MD, from the Fred Hutchinson Cancer Research Center in Seattle, Washington.

What is known is that B-cell aplasia represents the most common long-term adverse effect of CAR T-cell therapy. B-cell aplasia results when anti-CD19 CAR-T therapy wipes out healthy B cells as well as the malignant ones responsible for leukemia/lymphoma.

As major players in the immune system, B cells are a key defense against viruses. So B-cell aplasia represents a very specific type of immunosuppression. It is generally less severe than immunosuppression that occurs after organ transplant, which hits the immune system pretty much across the board and carries a much higher risk for infection.

The main concern is what happens when someone with B-cell aplasia encounters a new pathogen, such as SARS-CoV-2.

After infection, B cells generate memory cells, which are not killed off by anti-CD19 therapy and that stick around for life. So a patient such as Olson would still make antibodies that fight infections they experienced before receiving CAR-T therapy, such as childhood chickenpox. But now they are unable to make new memory cells, so these patients receive monthly immunoglobulin infusions to protect against pathogens they have not previously encountered.

Olson takes this in stride and says he isn't overly worried about COVID-19. He follows the recommended precautions for a man his age. He wears a mask, washes his hands frequently, and tries to maintain social distancing. But he doesn't stay locked up in his New Hampshire home.

"I took the attitude when I was diagnosed with cancer that I'm going to live my life," he said. "Quality of life to me is more important than quantity."

Another problem is the possibility of neuropsychiatric toxicity. Past studies have reported a wide range of such toxicities associated with CAR T-cell therapy, including seizures and hallucinations. Most have occurred early in the course of treatment and appear to be short-lived and reversible. However, there remain questions about long-term neuropsychiatric problems.

In a long-term study of 40 patients with relapsed/refractory CLL, non-Hodgkin lymphoma, and ALL, nearly half of patients (47.5%, 19/40) self-reported at least one clinically meaningful negative neuropsychiatric outcome (anxiety, depression, or cognitive difficulty) 1 to 5 years after anti-CD19 CAR T-cell therapy. In addition, 37.5% (15/40) self-reported cognitive difficulties.

"Patients with more severe neurotoxicity showed a trend for more cognitive difficulties afterwards," said Bar, senior author of the study.

However, teasing out the role that CAR T-cell therapy plays in these problems poses a challenge. All of these patients had been heavily pretreated with previous cancer therapy, which has also been associated with neuropsychiatric problems.

"So far, we don't know what caused it," Bar said. "Nevertheless, people need to pay attention to neuropsychiatric symptoms in CAR T-cell therapy. It is important to continue to monitor these patients for these issues."

Another potential problem is graft-vs-host disease (GVHD). This is not uncommon after hematopoietic stem cell transplants. It develops when the donor T cells view antigens on healthy recipient cells as foreign and attack them.

For patients who are treated with CAR T cells, GVHD is mostly a concern among individuals who have previously had a transplant and who are already at increased risk for it.

In a study of late effects among 86 adults treated with anti-CD19 CAR T cells for relapsed/refractory non-Hodgkin lymphoma, Bar and colleagues found that GVHD occurred only among patients who had received a previous donor stem cell transplant. Of these, 20% (3/15) developed GVHD about 28 months after CAR-T therapy.

"The data for CAR T cells causing GVHD really hasn't shown that it's a huge problem, although we have seen it and are continuing to monitor for it," the NCI's Shah commented to Medscape Medical News.

A range of other long-term adverse effects have been reported with CAR-T therapy, including prolonged cytopenias (reduced mature blood cells), myelodysplasia (bone marrow failure), and second malignancies.

In the study with the longest follow-up to date, 16% (7/43) of patients developed second malignancies, which is comparable to data from Bar's study in Seattle (15%, 13/86). The researchers in this study consider this rate to be no higher than expected: these patients had already received extensive chemotherapy, which increases the risk for other cancers, they point out.

However, this brings up theoretical concerns about the long-term effects of gene modification. CAR T cells are engineered using retroviruses (mainly lentiviruses), which randomly insert the CAR genes into the host genome. Doing so may cause mutations that could promote cancer. These lentiviruses also carry the theoretical risk of becoming capable of viral replication once inside the body.

To address these concerns, viruses used to engineer CAR T cells go through comprehensive safety testing. After therapy, patients are checked every few months during the first year and annually after that.

So far, there have been no reports of cancers associated with CAR T-cell therapy.

"Any type of cancer is a very theoretical risk," Bar told Medscape Medical News. "Most likely the malignancies in our study were related to prior treatment that the patients received. None of them had any evidence of replication-competent lentivirus, or any other evidence that the malignancies were related to the CAR T cells."

Another theoretical concern is the possibility of new-onset autoimmune disease, although, once again, no cases have been reported so far.

"We think of it as a theoretic possibility. Whenever you jack up the immune system, autoimmune disease is a potential risk," said Carl June, MD, director of the Center for Cellular Immunotherapies at the University of Pennsylvania.

June was the coprincipal investigator of the trial in which Olson participated. He is also the inventor on patents for CAR T cells licensed by the University of Pennsylvania to Novartis and Tmunity and is a scientific founder with equity in Tmunity.

Still, autoimmunity could occur, and scientists are looking out for it.

"We are continuing to be vigilant in our monitoring for autoimmune disease," Shah added. "We've been doing CAR T-cell therapy since 2012, and I think we have yet to see true autoimmunity beyond GVHD."

In the 10 years since Olson received CAR T-cell therapy, an entire industry has sprung up. Over 100 companies worldwide are now developing CAR T-cell therapies targeting various antigens. These therapies are directed at about 60 different tumor types, including solid tumors. Nearly 200 clinical trials are underway, though most are still in early stages: as of September 2019, only 5% had reached phase 3.

Clinical data show promising results for CAR T-cell therapy directed against CD22 (overexpressed on ALL cells), and BCMA (found on almost all multiple myeloma cells). Yet questions remain as to whether CAR T cells will be as effective if they target antigens other than CD19 or cells other than B lymphocytes. One of the biggest research questions is whether they will be effective against solid tumors.

One research avenue being watched with great interest is the development of universal CAR T cells. So far, such products are at very early stages of development (phase 1 trials), but they are attractive because of the potential advantages they offer over bespoke CAR T cells. Automating the process holds the promise of immediate availability, standardizing production, expanding access, and lowering costs. And because the T cells for this universal product come from healthy donors, they may function better than T cells that have been battered and bruised by past cancer treatments, or even the cancer itself.

However, precisely because they are developed from healthy donor T cells, universal CAR T cells may pose increased risk for GVHD. Scientists are trying to get around this problem by engineering universal CAR T cells that lack the T-cell receptor involved in GVHD.

There are also other concerns. Nature has a penchant for mutation. Engineering CAR T cells without T-cell receptors means the body may no longer detect or reject a universal CAR T cell if it goes rogue. Also, gene insertion in universal CAR-T therapy is targeted rather than random (as in bespoke CAR T cells), which could create off-target effects. Both issues create a theoretical risk of such products inducing an untreatable CAR T-cell therapyassociated cancer.

"The theoretic risk with universal cells is that their safety profile may not be as good for long term," June commented.

From that first trial in which June and Porter used CAR T cells, two of three patients they treated are still alive 10 years later.

Olson is one of these two, and he still undergoes monitoring every 3 months to check for relapse. So far, none of his tests have shown signs of his cancer returning.

After going into remission, Doug spent the next 6 to 9 months regaining his health and strength.

"I figured if I had this amazing treatment that saved my life, I had an obligation to stay alive," he said. "I'd better not die of something like a heart attack!"

He took up long distance running and has completed six half marathons. He became involved in the Leukemia and Lymphoma Society, participating in fund-raising and helping newly diagnosed patients. Over the years, he has also given talks for researchers, people with cancer, and healthcare providers.

Doug is now 73. Today, he marvels at how rapidly the CAR-T field has progressed.

"Twenty years ago, if you had cancer, your prospects weren't nearly as good as these days. In 2010, people still didn't believe in CAR T-cell therapy," he said. "My goal always in telling my story is a message of hope."

For more from Medscape Oncology, join us on Twitter and Facebook.

More here:
In Remission for 10 Years: Long-term Data on CAR-T Therapy - Medscape

MRFR predicts an Upsurge in the Leukemia Therapeutics Market valuation to USD 10.7 billion by 2023 – Jewish Life News

LeukemiaTherapeutics MarketOverview

The clinical condition an in which an increased number of abnormalleucocytesor generally called white blood cells of malignant characteristic is calledleukemia. Frequent infections, fever with chills and fatigue are early signs ofleukemia. Acute, chronic,lymphocytic, andmyelogenousleukemiasare classified underleukemia. Cancer statisticscenterof American Cancer Society estimates 61780 new cases ofleukemiain 2019. Treatment for such a malicious disease requires intense therapeutic attention. Therefore, the need for accurate treatment in the rising population ofleukemiapatients is the major factor impelling the globalleukemiatherapeutics market growth. The traditional therapies involved in the treatment ofleukemiaare chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant. The complex pathology ofleukemiademands advancements in medical infrastructure for treatment. Hence, letting the market key players immense opportunity to invest in research and development and bring forth innovation in theleukemiatherapy. This generates a lead for clinical researchers to investigate better drug administration methods. Efforts which are being made to deliver more effectiveleukemiatherapies is likely to trigger theleukemiatherapeutics market growth.

Get a FREE Sample with Complete TOCByConsidering the COVID-19 impact on Global Market @https://www.marketresearchfuture.com/sample_request/7425

However, on the flip side, the high cost of existingleukemiatherapies and investment required for developing new therapies is curbing theleukemiatherapeutics market expansion.

Globalleukemiatherapeutics market is expected to grow significantly over the forecast period. It is anticipated that the market held the value of USD 10.7 billion in 2017 and is projected to grow at a CAGR of 5.3% during the assessment period predicts Market Research Future (MRFR).

LeukemiaTherapeutics MarketSegmentalAnalysis

The globalleukemiatherapeutics market has been segmented into type, applications, and region.

Based on type, theleukemiatherapeutics market is segmented into chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant. The Chemotherapy segment which is anticipated to grow with the highest CAGR is further sub-segmented intoalkylatingagents,antimetabolites,antitumorantibiotics, and others.

Based on applications, theleukemiatherapeutics market is segmented into acutelymphocyticleukemia, acutemyelogenousleukemia, chroniclymphocyticleukemia, chronicmyelogenousleukemia, and others.

Based on region theleukemia therapeutics marketis segmented into North America, Europe, Asia-Pacific, and the Middle East & Africa. The Europeanleukemiatherapeutics market has been segmented into Western Europe and Eastern Europe. The Western Europe segment is further divided into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. Theleukemiatherapeutics market in Asia-Pacific has been further divided into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.

LeukemiaTherapeutics MarketRegional analysis

Reputed companies in North America manufacturing innovative and effective leukemic therapeutics is anticipated to bea majorforce allowing North America to dominate theleukemiatherapeutics market Growing numbers ofleukemiapatients in the European region is likely to drive theleukemiatherapeutics market in Europe in the upcoming years. Where theleukemiatherapeutics market in the Asia-Pacific region is likely to grow at a rapid rate, the Middle East & Africa is expected to show stagnancy in the market proliferation.

LeukemiaTherapeutics Industry Update

April 2019: Innovative Cellular Therapeutics (ICT), a clinical stage biotechnology company has achieved promisingpreclinicaland clinical results in late-stageleukemiaand lymphoma with novel CAR-T constructs. ICTCAR003, targets CD19 for the treatment of B-cell acutelymphoblasticleukemia.

Obtain Premium Research Report Details, Considering the impact of COVID-19 @https://www.marketresearchfuture.com/reports/leukemia-therapeutics-market-7425

About Market Research Future:

AtMarket Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by Components, Application, Logistics and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email:[emailprotected]

NOTE: Our team of researchers are studying Covid-19 and its impact on various industry verticals and wherever required we will be considering covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

Follow this link:
MRFR predicts an Upsurge in the Leukemia Therapeutics Market valuation to USD 10.7 billion by 2023 - Jewish Life News

QUANTRO Therapeutics Launched with Breakthrough Oncology Drug Discovery Platform – PharmiWeb.com

DGAP-News: QUANTRO Therapeutics GmbH / Key word(s): Financing/Miscellaneous 21.07.2020 / 07:30 The issuer is solely responsible for the content of this announcement.

QUANTRO Therapeutics Launched with Breakthrough Oncology Drug Discovery Platform

Vienna, Austria, 21 July 2020: QUANTRO Therapeutics GmbH today announced that the company has established its operations with seed financing from Boehringer Ingelheim Venture Fund (BIVF) and Evotec. As a research-based company, QUANTRO will combine and exploit innovative functional genetics and transcriptomics technologies to generate an unprecedented drug discovery pipeline transforming the precision and scope of cell-based compound screens. By introducing 'Transcriptional Fingerprinting' to drug discovery, QUANTRO intends to revamp the scope of pharmacologic interventions in a variety of cellular, target and disease contexts. A prime focus will be the discovery and development of drug candidates blocking the activity of oncogenic transcription factors, a class of particularly promising therapeutic targets that has so far remained largely unamenable to pharmacological intervention.

The company was founded by Dr. Stefan Ameres and Dr. Johannes Zuber as a spin-off of the Institute of Molecular Biotechnology (IMBA) and the Research Institute of Molecular Pathology (IMP), both located in Vienna, Austria. Bringing together expertise in time-resolved transcriptomics and functional genomics, the founders have pioneered innovative methods to study gene regulatory functions of oncogenic transcription factors and drugs in a variety of cellular models. Supported by two Proof-of-Concept grants of the European Research Council (ERC), they explored new applications of these cutting-edge technologies, thereby laying the groundwork for QUANTRO's discovery pipeline. Meanwhile, the team has been reinforced by extensive pharma R&D and senior executive experience with Dr. Dieter Nachtigall, who is a chemist by training and has been appointed CEO of QUANTRO. Boehringer Ingelheim Venture Fund and Evotec acquired equal minority stakes in QUANTRO and will be represented on the Company's Supervisory Board by Dr. Sebastian Kreuz and Dr. Dirk Ullmann, respectively. Furthermore, Evotec will provide hit identification services for QUANTRO's proprietary anti-tumor projects.

Dr. Dieter Nachtigall, Chief Executive Officer of QUANTRO, said: "QUANTRO Therapeutics has designed and set up a new discovery approach and technology platform based on world-leading scientific expertise by our founders and excellent support from our highly committed corporate venture partners. We are extremely motivated and ambitious to start operations in our facilities at the Startup Labs Vienna Biocenter and turn our vision of identifying and developing new anti-cancer agents with breakthrough potential into a reality."

Dr. Sebastian Kreuz, Boehringer Ingelheim Venture Funds, added: "The BIVF focuses on groundbreaking therapeutic approaches and technologies that have the potential to advance patient care in areas of high unmet medical need. We are looking forward to supporting QUANTRO and its dedicated founders to apply time-resolved RNA sequencing in an industrialized setting with the aim to unlock transcription factors as a highly promising target class for drug discovery in oncology and other disease areas."

Dr. Werner Lanthaler, Chief Executive Officer of Evotec, commented: "QUANTRO is a very promising academic spin-off company with great potential to lead the way in time-resolved RNA sequencing with a potentially ground-breaking technology to address 'undruggable' drug targets. Through our partnership and equity investment, we will further validate QUANTRO's approach and hope to be able to open many new doors across a broad range of therapeutic modalities together in the future."

Dr. Stefan Ameres, Founder and Scientific Advisor of QUANTRO, commented: "The definition of direct transcription factor targets and, more generally, the unbiased detection of direct transcriptional effects has remained challenging due to the limited time resolution of conventional techniques for gene perturbation and transcriptional profiling. Overcoming this hurdle adds great possibilities for new therapeutic interventions with previously inaccessible targets in different cancer types and disease contexts."

Dr. Johannes Zuber, Founder and Scientific Advisor of QUANTRO, added: "Transcription factors shape and maintain the identity of cancer cells and have long been recognized as promising therapeutic targets. After studying these factors and their therapeutic potential for many years, QUANTRO's discovery pipeline takes an unprecedented approach to finally exploit transcription factors for cancer therapy."

QUANTRO Management Board and Team Dr. Dieter Nachtigall, CEO of QUANTRO, holds a PhD in Analytical Chemistry and contributes 23 years in pharmaceutical research and development experience to QUANTRO. Additionally, he brings more than 10 years in senior executive roles at Boehringer Ingelheim.

Dr. Stefan Ameres, Founder and Scientific Advisor of QUANTRO, is a distinguished expert in RNA biology and transcriptomics and has since 2012 held the position of group leader at the IMBA, Vienna. Dr. Ameres has a track-record of highly ranked publications in Nature, Cell, Science and other peer-reviewed journals.

Dr. Johannes Zuber, also Founder and Scientific Advisor of QUANTRO, is a licensed MD and renowned expert in functional cancer genetics. He has been a group leader at the IMP, Vienna, since 2011, and his outstanding scientific accomplishments are documented in more than 160 publications in highly ranked journals.

For detailed CVs of the QUANTRO management board and Team, please visit website.com/management.

Contact QUANTRO Therapeutics GmbH Dr. Dieter Nachtigall, CEO Mail: dieter.nachtigall@quantro-tx.com http://www.quantro-tx.com

Media Contact MC Services AG Katja Arnold, Andreas Jungfer, Shaun Brown Phone: +49 89 210228 0 Mail: quantro@mc-services.eu

About QUANTRO Therapeutics GmbH QUANTRO Therapeutics ("QUANTRO") is a research-based entity that strives to discover and develop novel therapeutics interfering with disease-causing transcriptional programs in cancer and other diseases. QUANTRO will assemble a highly innovative drug-discovery pipeline that employs time-resolved RNA sequencing and comparative transcriptomics to identify and develop drug candidates interfering with transcriptional regulators. The first focus will be on cancer-associated transcription factors, which so far have been unamenable to pharmacologic intervention. QUANTRO was founded as a spin-off of the Institute of Molecular Biotechnology ("IMBA") and the Research Institute of Molecular Pathology ("IMP"), both located in Vienna, Austria. Seed investors are Boehringer Ingelheim Venture Fund and Evotec. For more information: http://www.quantro-tx.com

About Boehringer Ingelheim Venture Fund (BIVF) Created in 2010, the Boehringer Ingelheim Venture Fund GmbH (BIVF) invests in groundbreaking therapeutics-focused biotechnology companies to drive innovation in biomedical research. BIVF is searching for significant enhancements in patient care through pioneering science and its clinical translation by building long-term relationships with scientists and entrepreneurs. BIVF's focus is to target unprecedented therapeutic concepts addressing high medical needs in immuno-oncology, in regenerative medicine or infectious diseases. These may include novel platform technologies to address so far undruggable targets, new generation vaccines and/or new biological entities, such as oncolytic virotherapy as well as Digital Health.

BIVF takes an active role within its portfolio companies - delivering significant added value through its own extensive drug discovery, scientific and managerial expertise. BIVF has 300 million under management and currently supervises a portfolio of 29 companies. For more information, please visit http://www.boehringer-ingelheim-venture.com.

About EVOTEC SE Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide with more than 3,000 employees providing the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, fibrosis, rare diseases and women's health. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to http://www.evotec.com and follow us on Twitter @Evotec.

About IMP, IMBA and the Vienna BioCenter The Research Institute of Molecular Pathology (IMP) in Vienna is a basic biomedical research institute largely sponsored by Boehringer Ingelheim. With over 200 scientists from 40 countries, the IMP is committed to scientific discovery of fundamental molecular and cellular mechanisms underlying complex biological phenomena. http://www.imp.ac.at

IMBA - Institute of Molecular Biotechnology - is one of the leading biomedical research institutes in Europe focusing on cutting-edge stem cell technologies, functional genomics, and RNA biology. IMBA is a subsidiary of the Austrian Academy of Sciences, the leading national sponsor of non-university academic research. http://www.imba.oeaw.ac.at

Both IMP and IMBA are part of the Vienna BioCenter, one of Europe's most dynamic life science hubs with 1,800 employees from 70 countries in four research institutes, three universities and around 30 biotech companies. http://www.viennabiocenter.org

21.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

Read more:
QUANTRO Therapeutics Launched with Breakthrough Oncology Drug Discovery Platform - PharmiWeb.com

Orthopedic Regenerative Medicine Market Analysis and Forecast 2020: By Key players Curasan, Inc., Carmell Therapeutics Corporation, Anika…

Global Orthopedic Regenerative Medicine Market Research study which offers insights of in-depth research on historic and current market size along with the expected future prospects of the market and emerging trends in the market. The Orthopedic Regenerative Medicine Market report provides crucial information about the market, including Opinions from Industry experts, and the recent progressions and developments of the Orthopedic Regenerative Medicine Market.

Top Players in the Market are: Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.

Request Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/3566

To define and segment the market for Orthopedic Regenerative Medicine.

To analyse and forecast the market size & share of Orthopedic Regenerative Medicine, in terms of value and volume ($)

Raw Material Supply and Downstream Consumer Information are provided in Orthopedic Regenerative Medicine Industry report.

Market forecasts including market volumes, Value ($), Consumption is provided by regions, by types, and by applications.

|-=======================================================================-|

Our new sample is updated which correspond in new report showing impact of COVID-19 on Industry

|-=======================================================================-|

1- Country level analysis for any 5 countries of your choice.

2- Competitive analysis of any market players.

3- 40 analyst hours to cover any other data points

4- Research framework (presentation)

5-Table of Contents (Scope covered as a part of the study)

Detailed Segmentation:

By Procedure Cell TherapyTissue EngineeringBy Cell TypeInduced Pluripotent Stem Cells (iPSCs)Adult Stem CellsTissue Specific Progenitor Stem Cells (TSPSCs),Mesenchymal Stem Cells (MSCs)Umbilical Cord Stem Cells (UCSCs)Bone Marrow Stem Cells (BMSCs)By SourceBone MarrowUmbilical Cord BloodAdipose TissueAllograftsAmniotic FluidBy ApplicationsTendons RepairCartilage RepairBone RepairLigament RepairSpine RepairOthers

Major Key players Like: Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.

Regions included:

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Get your special Discount on Direct [emailprotected] https://www.coherentmarketinsights.com/insight/request-discount/3566

**including TOC, figures and Chart+30 minutes of consultation

Key Highlights of the Table of Contents:

Orthopedic Regenerative Medicine Market Study Coverage: It includes key manufacturers covered, key market segments, Furthermore, it

Touches the segmentation study provided in the report on the basis of the type of product and applications.

Orthopedic Regenerative Medicine Market Executive Summary: This section emphasizes on the key studies, market growth rate,

Competitive landscape, market drivers, trends, and issues in addition to the macroscopic indicators.

Orthopedic Regenerative Medicine Market Production by Region: The report provides information related to import and export,

Production, revenue, and key players of all regional markets studied are covered in this section.

Orthopedic Regenerative Medicine Market Profile of Manufacturers: Analysis of each market player profiled is detailed in this

Section. This also provides SWOT analysis, products, production, value, capacity, and other vital factors of

The individual player.

Get PDF Brochure @https://www.coherentmarketinsights.com/insight/request-pdf/3566

Orthopedic Regenerative Medicine Market Report provides an in-depth analysis of the overall market, the ripple effect of Coronavirus-Covid19 on the market needs to become part of strategy discussions to emerge strong. The report focuses on major key players, production details, their application, countries and also analyzes the global and key regions market potential and advantage, opportunity, and challenge, restraints, and risks.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact US

Mr.Shah Phone: US +1-206-701-6702/UK +44-020 8133 4027 [emailprotected]

See the original post:
Orthopedic Regenerative Medicine Market Analysis and Forecast 2020: By Key players Curasan, Inc., Carmell Therapeutics Corporation, Anika...

Amniotic Membranes Market is Projected to Expand at a CAGR of ~10% from 2019 to 2027 – 3rd Watch News

Transparency Market Research (TMR) has published a new report on the amniotic membrane market for the forecast period of 2019-2027. According to the report, the global amniotic membrane market was valued at ~US$ 980 Mn in 2018 and is projected to expand at a CAGR of ~10% from 2019 to 2027.

Global Amniotic Membrane Market: Overview

Request a PDF Brochure https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=42059

Increase in Research on Stem Cell Biology & Regenerative Medicine to Drive Market

Cryopreserved Amniotic Membrane Products to Dominate Market

Request for Analysis of COVID19 Impact on Amniotic Membranes Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=42059

Ophthalmology to be Promising Application

Hospitals Account for Major Share of Global Market

North America to Dominate Global Amniotic Membrane Market

Buy Amniotic Membranes Market Report https://www.transparencymarketresearch.com/checkout.php?rep_id=42059&ltype=S

Global Amniotic Membrane Market: Competitive Landscape

More Trending Reports by Transparency Market Research

Virus Filtration Market: https://www.prnewswire.co.uk/news-releases/global-virus-filtration-market-to-expand-as-researchers-focus-on-improving-testing-technologies-tmr-877745218.html

Read our Case study at https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

View post:
Amniotic Membranes Market is Projected to Expand at a CAGR of ~10% from 2019 to 2027 - 3rd Watch News

Platelet-Rich Plasma for the Knee: Does It Work?

Key points

Injections of platelet-rich plasma (PRP) are a novel treatment for managing pain related to osteoarthritis (OA) of the knee. Researchers are still investigating this option.

Some PRP preparations have approval from the Food and Drug Administration (FDA), but approval does not yet cover the use of PRP in OA of the knee. Nevertheless, some clinics may offer it off-label.

Current guidelines from the American College of Rheumatology and the Arthritis Foundation (ACR/AF) strongly recommend avoiding this treatment because it has not yet been fully developed and standardized. This means you cannot be sure of what your dose contains.

With further research, however, it could become a useful treatment option. Read on to learn more about PRP and other options for treating OA.

The platelets in your blood contain growth factors. Scientists believe that injecting PRP growth factors from your own blood into an injured area will help tissues repair themselves by causing new cells to form.

In this way, PRP could help reverse existing tissue damage.

Evidence about using PRP to treat knee OA has not yet confirmed that it is a safe and effective option, and studies have produced conflicting results.

While many studies support its use, many others say PRP has no effect, according to a 2019 review.

A 2017 review looked at 14 randomized controlled trials with a total of 1,423 participants. Results suggested that PRP may help manage pain associated with knee OA.

The authors noted the following at 3-, 6-, and 12-month follow-ups:

Pain levels: Compared with placebos, PRP injections significantly reduced pain scores at each follow-up appointment.

Physical function: Compared with controls, PRP significantly improved physical function at these follow ups.

Adverse effects: Some people experienced adverse effects, but these were no more significant than those produced by other types of injection.

While the results appear promising, 10 of the 14 studies reviewed had a high risk of bias, and four had a moderate risk of bias.

More studies are needed to determine whether PRP could offer a suitable option to manage pain from OA of the knee.

PRP is an experimental therapy, and experts do not currently recommend its use. If you are considering PRP injections, start by asking your doctor for their advice.

Since PRP injections are experimental, there is limited evidence about how safe and effective they are. In addition, your insurance policy may not cover them.

Work closely with your doctor before starting any experimental treatments, and ensure that any provider is fully qualified to offer this treatment.

First, your doctor will draw a small amount of blood from your arm.

Then, theyll put the blood sample into a centrifuge to separate the components and obtain a concentrated suspension of platelets in plasma. At this point, variations in procedure may lead to different concentrations of the various components.

Next, the doctor will numb your knee and inject the PRP into the joint space in the knee. They may use ultrasound to guide the injection.

After resting a while, you will be able to go home. You should arrange for someone to drive you home, as there may be pain and stiffness after the injection.

After the procedure, your doctor may advise you to:

You may need to use crutches or a walking frame for a few days to keep the weight off of your knee.

Follow your physicians advice about follow-up appointments.

PRP uses your own blood, so experts say it is likely to be safe.

However, an injection into the knee joint can entail some risks, including:

The 2017 review mentioned above found that some people experienced:

However, the researchers noted that these were non-specific and no more significant than the side effects of other injections.

Moreover, the cost of this type of treatment can be high, and insurers may not cover it. Find out how much it is likely to cost before you go ahead.

Bear in mind also that there may be unforeseen adverse effects, due to the experimental nature of the treatment.

There are various ways to manage OA-related pain and other symptoms. Weight management and exercise are key long-term strategies, but other options can provide more immediate relief.

Learn more about the treatment options for OA.

PRP injections use your own blood to stimulate growth in injured tissues. There is some evidence that this treatment may help manage pain associated with OA of the knee, but not enough to confirm that it works.

Experts do not currently recommend PRP injections for OA of the knee, due to the lack of standardization at the preparation stage.

If you are considering PRP, be sure to discuss it first with your doctor and follow their advice. Remember that it is an experimental treatment that clinics can only provide off-label.

Can diet help manage OA of the knee?

See original here:
Platelet-Rich Plasma for the Knee: Does It Work?

Stem Cell Therapy Market 2020 Recent Industry Developments and Growth Strategies Adopted by Top Key Players Worldwide and Assessment to 2026 – Cole of…

Lets begin with, why research is important for Stem Cell Therapy Market? It is always important because it gives direction to deal with a specific problem. Report Ocean has recently published a market research report on the Stem Cell Therapy Market which will provide you a leading direction of Stem Cell Therapy Market. This research report keenly focusses on development status and recent trends of the Stem Cell Therapy Market, along with competitive landscape, supply chain, market dynamics (opportunities, restraints, and drivers), government policies and opportunities.

The Stem Cell Therapy Market report provides a detailed analysis of the global market size, regional and country-level market size, segment growth, market share, competitive landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunity analysis, strategic market growth analysis, product launches, and technological innovations.

COVID 19 Impact on Stem Cell Therapy Market

This research study also includes the analyses related to the impact of Covid-19 on the Stem Cell Therapy Market. The global impacts of the coronavirus disease 2019 (COVID-19) may significantly affect the growth of the Stem Cell Therapy Market in near future. As per the experts viewpoints, it affects the global economy in 3 major ways:

By directly affecting demand and production chain

By creating market disturbance and supply chain

By impacting the firms financially and influencing the financial markets

Request Free Sample Report athttps://www.reportocean.com/industry-verticals/sample-request?report_id=mai26603

Competitive Landscape:

Key players in the global Stem Cell Therapy market covered in Chapter 4: Anterogen Caladrius RTI Surgical BIOTIME Osiris Therapeutics Pharmicell AlloSource MEDIPOST JCR Pharmaceuticals BrainStorm Cell Therapeutics Holostem Terapie Avanzate Advanced Cell Technology NuVasive

In this chapter will provide you a complete description of competitors and their relative position in Stem Cell Therapy Market. We will provide you the information about major players, their products, prices, market share, current strategies and main strengths and weaknesses. In this competitive world, it is indispensable to understand who the rivals are and how they usually perform with the purpose of improving its own market position. Direct and indirect competitors should be identified and analyzed. This valuable information will support decision makers when defining and evaluating company strategies.

Market Segmentation:

For a business to grow, you always need to look at the specific group of consumers. It also helps you to avoid the cost of advertising and distributing to a mass market. In this section, we mainly focused on subdivision of the Stem Cell Therapy Market into compatible subsections of customers where any subsection may be selected as a market target to be reached with a unique marketing mix

Geographically, the report includes the detailed research on market share, growth rate, consumption, production, revenue and forecast of the following regions:

United States

Central and South America (Brazil, Mexico, Colombia)

Europe (Germany, UK, France, Italy, Spain, Russia, Poland)

China

Japan

India

Southeast Asia (Malaysia, Singapore, Philippines, Indonesia, Thailand, Vietnam)

Middle East and Africa (Saudi Arabia, United Arab Emirates, Turkey, Egypt, South Africa, Nigeria)

Some of the Major Highlights of TOC covers:

Report Overview

Study Scope

Key Market Segments

Regulatory Scenario by Region/Country

Market Investment Scenario Strategic

Global Market Growth Trends

Industry Trends

SWOT Analysis

Porters Five Forces Analysis

Potential Market and Growth Potential Analysis

Industry News and Policies by Regions

Industry News

Industry Policies

Industry Trends Under COVID-19

Value Chain of Stem Cell Therapy Market

Value Chain Status

Stem Cell Therapy Market Manufacturing Cost Structure Analysis

Production Process Analysis

Manufacturing Cost Structure of Stem Cell Therapy Market

Labor Cost of Stem Cell Therapy Market

Labor Cost of Stem Cell Therapy Market Under COVID-19

Sales and Marketing Model Analysis

Downstream Major Customer Analysis (by Region)

Value Chain Status Under COVID-19

Stem Cell Therapy Market Production, Revenue (Value), Price Trend by Type

Production and Market Share by Type

Revenue and Market Share by Type

Price by Type

Stem Cell Therapy Market Production, Consumption, Export, Import by Region

Production, Consumption, Export, Import by Region

Production, Consumption, Export, Import by Country

Production, Revenue, Price and Gross Margin

Industrial Chain, Sourcing Strategy and Downstream Buyers

Stem Cell Therapy Market Industrial Chain Analysis

Raw Materials Sources of Stem Cell Therapy Market major Players in 2019

Downstream Buyers

Stem Cell Therapy Market Forecast

Stem Cell Therapy Market Sales, Revenue and Growth Rate

Stem Cell Therapy Market Production, Consumption, Export and Import Forecast by Region

Stem Cell Therapy Market Production, Revenue and Price Forecast by Type

Stem Cell Therapy Market Consumption Forecast by Application

Stem Cell Therapy Market Forecast Under COVID-19

Years considered for this report:

Historical Years: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2020-2026

For more information and discount on this report, ask your query at:https://www.reportocean.com/industry-verticals/sample-request?report_id=mai26603

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, and Asia.

Contact Us: +1 888 212 3539 (US) +91-9997112116 (Outside US) Contact Person: Matthew S Email:[emailprotected]

Read more:
Stem Cell Therapy Market 2020 Recent Industry Developments and Growth Strategies Adopted by Top Key Players Worldwide and Assessment to 2026 - Cole of...